-

Parnell Launches Pentobarbital Sodium and Phenytoin Sodium Euthanasia Solution for Dogs

Dependable Solution for Compassionate and Humane Care

OVERLAND PARK, Kan.--(BUSINESS WIRE)--Parnell today announced the launch of Pentobarbital Sodium and Phenytoin Sodium Euthanasia Solution, a Class III controlled veterinary product formulated for humane, painless, and rapid euthanasia of dogs, available in 100 mL multi‑dose vials.

Designed for clinical reliability and ease of identification in practice settings, Parnell’s formulation contains 390 mg/mL pentobarbital sodium and 50 mg/mL phenytoin sodium, with Rhodamine B (bluish‑red dye) to clearly distinguish it from parenteral drugs intended for therapeutic use.

“At Parnell, we understand the responsibility veterinarians carry during end‑of‑life care,” said Pablo Lamberto, DVM, SVP and President of U.S. Operations for Parnell. “We are proud to offer a solution that supports compassionate, calm, and dignified experiences for dogs and the people who care for them.”

Parnell’s Pentobarbital Sodium and Phenytoin Sodium Euthanasia Solution is now available to U.S. veterinary practices via distributor partners. For more information, visit www.parnell.com or contact your local distributor representative.

About Parnell Pet Care

Parnell’s Pet Care portfolio includes PropofolVet Multidose (propofol injectable emulsion), Parnell Brand Dexmedetomidine Hydrochloride Injection, CONTRASED™ (atipamezole hydrochloride), Parnell Brand Isoflurane Inhalation Anesthetic, and Parnell Brand Pentobarbital Sodium and Phenytoin Sodium Euthanasia Solution. To further support veterinary success, Parnell offers the Foundations of Anesthesia & Sedation Certificate Program, an online course providing 10 RACE-approved CE hours. Together, these offerings empower veterinary professionals to deliver confident, high‑quality care through every stage of the patient journey.

About Parnell

Parnell is a veterinary pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions. We currently manufacture and market products for companion and production animals in 10 countries. Discover more at www.parnell.com.

©2026 Parnell Technologies Pty LTD. CONTRASED is a trademark of Parnell Technologies Pty LTD. MKT-26-047 PC US

Contacts

Media Contact:
Angela Kille
Associate Director of Strategic Marketing
angela.kille@parnell.com
913-274-2100

Parnell


Release Versions

Contacts

Media Contact:
Angela Kille
Associate Director of Strategic Marketing
angela.kille@parnell.com
913-274-2100

Social Media Profiles
More News From Parnell

Parnell Expands Veterinary Anesthesia Portfolio with Isoflurane

OVERLAND PARK, Kan.--(BUSINESS WIRE)--Parnell is proud to announce the launch of its new Isoflurane Inhalation Anesthetic, a nonflammable and nonexplosive solution designed for the induction and maintenance of general anesthesia in horses and dogs. Available in 250 mL bottles, Parnell’s Isoflurane provides veterinary clinics with a reliable, cost-effective alternative to existing options, ensuring safe and efficient anesthesia care. “We are pleased to introduce Isoflurane as part of Parnell’s c...
Back to Newsroom